Related Experiment Videos
Warfarin dose related to apolipoprotein E (APOE) genotype
Hugo Kohnke1, Kristina Sörlin, Göran Granath
1Department of Medical Sciences, Clinical Pharmacology, University Hospital, 75185, Uppsala, Sweden.
European Journal of Clinical Pharmacology
|June 14, 2005
Summary
The apolipoprotein E (APOE) E4 allele is linked to higher warfarin doses in individuals with normal CYP2C9 activity. This suggests APOE genotype influences vitamin K metabolism and anticoagulant therapy needs.
Area of Science:
- Pharmacogenomics
- Clinical Biochemistry
Background:
- Warfarin is an anticoagulant affecting vitamin K recycling and clotting factor activation.
- Apolipoprotein E (APOE) influences lipid-soluble vitamin K uptake.
- APOE gene variations (E2, E3, E4) encode different apolipoprotein E isoforms.
Purpose of the Study:
- To investigate the influence of apolipoprotein E (APOE) gene variations on required warfarin dosage.
Main Methods:
- APOE genotyping was performed on 183 warfarin-treated patients.
- Clinical data including warfarin dose and CYP2C9 genotype were collected.
- Patients were stratified based on CYP2C9 genotype.
Main Results:
- Patients homozygous for APOE*E4 tended to require higher warfarin doses.
- Among CYP2C9 extensive metabolizers, APOE*E4 homozygotes needed significantly higher doses (56.9 mg/week) versus others (34.3-34.6 mg/week).
- APOE genotype accounted for 6% of warfarin dose variance in CYP2C9 extensive metabolizers.
Conclusions:
- Individuals with APOE*E4 alleles may have increased vitamin K uptake.
- This enhanced vitamin K uptake could necessitate higher warfarin doses for effective anticoagulation.
- APOE genotype is a potential factor in personalized warfarin dosing.